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The mutual association between permeability barrier dysfunction and allergic inﬂammation is one of the
most important issues in the pathogenesis of atopic dermatitis (AD). Permeability barrier abrogation not
only induces cutaneous inﬂammation, but is also involved in the induction of T helper 2 (Th2)-type
immunological reactions. Conversely, Th2 or other cytokines abrogate permeability barrier homeostasis.
Some molecules and/or pathogenic factors have been found to be simultaneously involved in both as-
pects of AD. Decreases in ﬁlaggrin or peroxisome proliferator-activated receptor a, which are observed in
AD lesions, not only disturb the permeability barrier function but could also directly augment cutaneous
inﬂammation via the upregulation of proinﬂammatory cytokines. Elevation of the stratum corneum (SC)
pH, which is also observed in AD lesions, could initiate and/or drive many of the pathogenic features
including both the permeability barrier disturbance and induction of Th2-type inﬂammation via
protease-activated receptor-2-dependent and -independent mechanisms, leading to the emergence and/
or exacerbation of AD. Disturbance of the SC pH recovery function is observed in ﬂaky tail mice and
might be involved in the susceptibility to AD-like dermatitis of mice with genetic abnormalities asso-
ciated with permeability barrier function. Disturbed SC acidity maintenance could be regarded as a
missing link that connects genetic abnormalities associated with permeability barrier dysfunction and
environmental factors in the pathogenesis of AD.
Copyright © 2015, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
The mutual association between permeability barrier dysfunction
and allergic inﬂammation is one of the most important issues in the
pathogenesis of atopic dermatitis (AD).1 This review ﬁrst describes
the cross-talk between these two aspects of AD. Next, some path-
ogenic molecules or factors that could be simultaneously involved
in both aspects are described. Finally, this review proposes a
possible mechanism by which genetic abnormalities associated
with impaired permeability barrier function collaborate with
environmental factors, resulting in the emergence and/or exacer-
bation of AD.y have no ﬁnancial or non-
atter or materials discussed
ita University, 1-1 Idaigaoka,
cal Association. Published by ElsevMutual association between permeability barrier abnormality
and allergic inﬂammation
Permeability barrier abrogation induces the production and secre-
tion of a variety of proinﬂammatory cytokines, such as interleukin
(IL)-1a, tumor necrosis factor (TNF) a, granulocyte macrophage
colony-stimulating factor (GM-CSF), and IL-6. Therefore, repetitive
permeability barrier abrogation alone causes substantial cutaneous
inﬂammation via excess production of proinﬂammatory cytokines.2
It has been shown that barrier abrogation-induced inﬂammation is
accompanied by a T helper 2 (Th2)-type reaction with eosinophilic
inﬁltration and expression of the chemokines thymus and
activation-regulated chemokine (TARC) and regulated on activation
normal T cell expressed and secreted (RANTES).3 Permeability bar-
rier abrogation also increases stratum corneum (SC) pH, thereby
initiating a variety of cascades that induce or augment inﬂamma-
tion, including induction of Th2 type inﬂammation, in a protease-
activated receptor (PAR) 2 activation dependent or independentier Taiwan LLC. All rights reserved.
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production, PAR2 activation following permeability barrier abro-
gation stimulates the production of thymic stromal lymphopoietin
(TSLP) in keratinocytes.4,5 The induction of a Th2-type immuno-
logical reaction by sensitization through permeability barrier-
abrogated skin is now thought to be involved in the emergence of
allergic disorders in multiple organs, such as asthma, rhinitis, and
food allergy.6e8
Conversely, it has been recognized that allergic inﬂammation
disturbs the permeability barrier function. First, involvement of Th2
cytokines in permeability barrier dysfunction has been elucidated.
IL-4 inhibits the upregulation of ceramide synthesis by TNFa and
interferon (IFN) g or by permeability barrier abrogation, thus
resulting in disturbance of permeability barrier homeostasis.9,10
IL4, IL-13, and IL-31 reduce the expression of epidermal
differentiation-related molecules such as involucrin, loricrin, and
ﬁlaggrin, which are important elements in permeability barrier
homeostasis.11e13 In addition, Th2 cytokines upregulate the
expression of kallikrein-related peptidase 7,which accounts for the
degradation of corneodesmosomes,14 and downregulates expres-
sion of desmoglein 1, which is one of the most important compo-
nents of corneodesmosomes.15 The combined data suggest that Th2
cytokines have negative effects on permeability barrier homeo-
stasis and SC integrity/cohesion.
A variety of cytokines other than Th2 cytokines are also known
to disturb permeability barrier function. IL-17 and IL-22 reduce the
expression of ﬁlaggrin, proﬁlaggrin processing enzymes, cellular
adhesion-related molecules, and tight junction (TJ)-related mole-
cules.16,17 IFNg, TNFa, and IL-25 also reduce the expression of
ﬁlaggrin.18e20
Cutaneous inﬂammation disturbs the TJ barrier,21 resulting in
disturbance of the SC barrier.21,22 An increase in SC pH might be
involved in SC barrier dysfunction due to abrogation of the TJ
barrier.22
Possible mechanisms for simultaneous involvement in both
permeability barrier dysfunction and allergic inﬂammation
As described above, the mutual association between permeability
barrier dysfunction and allergic inﬂammation, which results in a
vicious cycle of both aspects, is an important issue in the patho-
genesis of AD, and management of both aspects is essential for the
treatment of patients with AD. In this context, it is rational to seek
therapeutic strategies that take both aspects into account. Indeed,
recent advances related to this issue have implicated some mole-
cules or pathogenic factors that account for both aspects simulta-
neously and, which, therefore, could serve as promising targets for
the development of new therapeutic strategies.
Filaggrin
Filaggrin is an important epidermal differentiation-related mole-
cule and plays critical roles in permeability barrier homeostasis.
Interestingly, it has been recently shown that keratinocytes trans-
fected with small interfering RNA against the proﬁlaggrin gene can
produce greater quantities (vs. control) of TSLP, which is an
essential cytokine for the induction of the Th2-type immunological
reaction.23 It has also been reported that the keratinocytes of ﬂaky
tail mice, in which ﬁlaggrin is deﬁcient owing to a loss-of-function
mutation of proﬁlaggrin, produce more of the proinﬂammatory
cytokine, IL-1b, compared with those of wild-type mice.24 These
results illustrate that an abnormality in a barrier-related molecule
could, simultaneously, modulate the functions relevant to allergic
inﬂammation in keratinocytes. Expression of ﬁlaggrin is known to
be downregulated genetically or secondarily (i.e., via allergicinﬂammation as described above) in AD.1,11 Therefore, strategies
aimed at augmentation of ﬁlaggrin expression could not only
restore barrier function but could also reduce susceptibility to
allergic inﬂammation, thereby preventing the emergence of the
vicious cycle in AD. Indeed, it has been reported that augmentation
of ﬁlaggrin prevented the emergence of AD-like dermatitis in a
murine model.25
Peroxisome proliferator-activated receptor a
Peroxisome proliferator-activated receptors (PPARs) belong to the
nuclear hormone receptors class II, and have three sub-
typesdPPARa, PPARb/d, and PPARg.26 They are called liposensors
because their ligands are lipids or lipid derivatives. Generally, PPAR
signaling has positive effects on barrier homeostasis, but it can also
have anti-inﬂammatory effects, although there are several differ-
ences between the PPAR subtypes. The activation of PPARs stimu-
lates lipid synthesis and epidermal differentiation and accelerates
recovery from permeability barrier dysfunction.26 Moreover, the
development of the epidermal barrier is delayed in PPARa-deﬁcient
mice.27 Activators of PPARa suppress both allergic and irritant
cutaneous inﬂammation in vivo.28 Interestingly, it has been re-
ported that PPARa expression in the skin is reduced in patients with
AD and that PPARa-deﬁcient mice develop hapten-induced AD-like
dermatitis more easily than wild-type mice.29 In addition, the
expression of PPARa in the epidermis is reduced in similar hapten-
induced murine AD models, and topical treatment with some
PPARa activators exhibits a substantial therapeutic effect onmurine
AD both by restoring the permeability barrier function and by
stopping allergic inﬂammation.30,31 Finally, we recently demon-
strated that expression of TARC and RANTES was upregulated, and
expression of transglutaminase 1 and loricrin was downregulated,
in cultured human keratinocytes by transfection with small inter-
fering RNA for PPARa.32 The combined data indicate that depressed
PPARa expression might be involved in the pathogenesis of AD via
simultaneous involvement in both allergic inﬂammation and
permeability dysfunction and could be a rational therapeutic target
that accounts for both aspects.
SC pH
Elevation of SC pH, a universal accompaniment to barrier defects, as
well as to inﬂammation and environmental factors such as the use
of alkaline soaps, are features of AD, and are likely to be “drivers” of
several pathogenic features of AD, including both the permeability
barrier disturbance and induction of Th2-type inﬂammation.1 The
pathological consequences of an elevation in SC pH are thought to
include two divergent pathwaysdPAR-2-dependent and -inde-
pendent mechanisms. PAR2-independent, downstream effects
include reduced activities of two key lipid processing enzymes, i.e.,
b-glucocerebrosidase (b-GlcCer'ase) and acidic sphingomyelinase,
which exhibit an acidic pH optimum, resulting in delayed matu-
ration of lipid bilayers.1 An increase in SC pH also activates the
kallikrein family of serine proteases in the outer epidermis, which
accelerate the destruction of barrier-related components such as
lipid processing enzymes and corneodesmosomes, while gener-
ating the active forms of IL-1a and IL-1b.1 By contrast, the receptor-
dependent activation of PAR2 triggers Th2-type inﬂammation via
the production of a variety of proinﬂammatory cytokines and TSLP
in epidermal keratinocytes, and induction of mast cell degranula-
tion.1,33 Accordingly, the maintenance of an acidic pH largely pre-
vented the appearance of AD and the emergence of atopic march-
like phenomena in repeatedly hapten-challenged mice.34,35 In
addition, a PAR2 antagonist, NPS1577, attenuated the emergence of
allergen-induced AD-like dermatitis in ﬂaky tail mice, suggesting
Figure 1 Possible hypothesis on the pathogenesis of atopic dermatitis. Based on the contents in the present review, a possible story could be made on the pathogenesis of atopic
dermatitis (AD). Genetic abnormalities associated with impaired permeability barrier not only cause permeability barrier dysfunction but also could be directly involved in sus-
ceptibility to cutaneous inﬂammation, leading to the subclinical state. At the subclinical state, it may get difﬁcult to maintain stratum corneum (SC) acidity following the elevation of
SC pH by the environmental factors equivalent to SC neutralization stimuli. In concert with the environmental factors, substantial cutaneous inﬂammation emerges and a vicious
cycle is operated, resulting in AD. Der. ¼ dermis; Epi. ¼ epidermis; Ker. ¼ keratinocyte; SC ¼ stratum corneum.
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combined data suggest that abrogation of SC acidity and/or PAR2
signaling could be therapeutic targets for simultaneous mediation
of both allergic inﬂammation and permeability barrier dysfunction.
Possible mechanisms for collaboration of genetic
abnormalities associated with impaired epidermal barrier
and environmental factors
Collaboration of the genetic background associated with impaired
epidermal barrier with environmental factors is essential in the
emergence of AD. However, the mechanism by which people with
genetic abnormalities related to the skin barrier show susceptibility
to allergic inﬂammation when suffering from environmental fac-
tors, remains obscure. Of note, environmental factors such as
scratching, the use of alkali soap, and low humidity are generally
involved in permeability barrier abrogation, leading to an elevation
of SC pH. As mentioned above, elevation of SC pH could trigger or
drive many pathways leading to the emergence and/or exacerba-
tion of AD. Therefore, disturbance of the maintenance of SC acidity
might be the missing link that connects genetic abnormalities
associated with an impaired epidermal barrier and environmental
factors. Interestingly, it has been recently revealed that SC recovery
function following elevation of SC pH is disturbed in ﬂaky tail mice,
which have two genetic abnormalities associated with the
permeability barrier (i.e., ﬁlaggrin and Tmem79/Matt).37 Thus,
disturbance of the maintenance of SC acidity might be involved in
the susceptibility of ﬂaky tail mice to AD-like dermatitis. Indeed, in
these mice, a compensatory mechanism for the maintenance of SC
acidity, i.e., elevation of sodium/proton pump Nþ/Hþ antiporter 1
(NHE1) activity, was already fully exploited at the steady state,
presumably because of subclinical permeability barrier abrogation
and/or inﬂammation caused by the genetic abnormalities, with the
result that it could not compensate for exogenous SC-neutralization
stimuli.37
Conclusion
It is essential to investigate the mutual association between
permeabilitybarrierdysfunctionandallergic inﬂammation to clarify
the pathogenesis of AD. Such investigations could not only elucidate
the complicated pathogenesis in which genetic abnormalities andenvironmental factors collaborate in a sophisticated manner, but
also sow the seeds of new scientiﬁc and therapeutic strategies in AD
(Figure 1).References
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